ZUG, Switzerland, May 20, 2026
Implantica AG announced that it has submitted its final response to the U.S. Food and Drug Administration (FDA) regarding the company’s Premarket Approval (PMA) application for RefluxStop®, a next-generation implantable device developed for the treatment of gastroesophageal reflux disease (GERD). The submission marks a major regulatory milestone for Implantica as the company moves closer toward potential commercialization of RefluxStop® in the United States, one of the world’s largest healthcare markets for reflux treatment technologies.
According to Implantica, the latest submission includes responses to all remaining FDA questions related to Module 3 of the PMA application, along with completion of additional testing requested by the Agency following the previously held 100-Day Meeting. The company confirmed that all six FDA preapproval inspections, including manufacturing site audits, Quality System evaluations, and BIMO clinical trial inspections, were successfully completed.
The announcement represents a significant development within the growing market for advanced GERD treatment solutions, where healthcare providers continue seeking safer and more effective alternatives to conventional anti-reflux surgical procedures.
RefluxStop Designed to Transform GERD Surgery
GERD affects an estimated one billion people globally, making it one of the most prevalent chronic gastrointestinal disorders worldwide. Many patients experience persistent acid reflux symptoms despite long-term medication use, often requiring surgical intervention to improve quality of life and prevent complications such as esophageal damage, chronic inflammation, and sleep disturbances.
Advertisement
Unlike traditional anti-reflux surgical procedures that rely on wrapping or compressing the esophagus, RefluxStop® was specifically designed to restore the body’s natural anatomy while preserving normal physiological function. Implantica stated that the implant aims to reconstruct the body’s natural anti-reflux barrier without compressing the food passageway, potentially reducing side effects commonly associated with conventional surgical treatments such as difficulty swallowing, gas bloating, and inability to belch or vomit.
The PMA application is supported by extensive long-term clinical evidence, including data from the company’s pivotal clinical study featuring a five-year follow-up requested by the FDA. Implantica noted that the study findings have already been published in peer-reviewed scientific journals demonstrating strong long-term safety and efficacy outcomes for RefluxStop®.
Healthcare experts believe innovative implantable GERD therapies may significantly improve patient outcomes as demand rises for minimally disruptive surgical approaches that preserve normal digestive function while effectively controlling reflux symptoms.
FDA Review Marks Key MedTech Milestone
Implantica founder and CEO Dr. Peter Forsell described the FDA submission as the culmination of years of scientific, clinical, regulatory, and operational work aimed at bringing RefluxStop® to U.S. patients. The company also highlighted increasing interest from leading surgeons and gastroenterologists who continue evaluating the technology as a potential advancement in reflux surgery.
Industry analysts note that successful FDA approval could position RefluxStop® as a disruptive innovation within the anti-reflux surgery market, particularly because current surgical standards still face limitations related to patient tolerability and post-procedural complications. The company believes its device’s unique mechanism of action could potentially redefine treatment expectations in GERD management.
The FDA PMA process remains one of the most rigorous regulatory pathways for medical devices in the United States, particularly for implantable technologies involving long-term patient safety and efficacy considerations. Successful completion of multiple preapproval inspections demonstrates substantial regulatory progress and manufacturing readiness for future commercialization activities.
Implantable Technologies Continue Expanding in Healthcare
Beyond RefluxStop®, Implantica continues developing a broader portfolio of advanced implantable medical technologies supported by patent-protected innovation platforms. The company is also advancing an eHealth platform designed for communication and remote monitoring of implants inside the body, along with a wireless energizing platform capable of powering implantable devices through intact skin.
Medical technology experts believe next-generation implantable systems integrated with digital monitoring capabilities may become increasingly important across gastrointestinal, cardiovascular, neurological, and chronic disease management applications in the coming decade.
Implantica stated that it now looks forward to completion of the FDA PMA review process and eventual introduction of RefluxStop® to U.S. patients pending regulatory approval. The announcement underscores the growing momentum behind innovative implantable MedTech solutions focused on improving long-term patient outcomes while minimizing treatment-related complications.
Source: Implantica press release
